|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BOLA3 |
Gene summary for BOLA3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BOLA3 | Gene ID | 388962 |
| Gene name | bolA family member 3 | |
| Gene Alias | MMDS2 | |
| Cytomap | 2p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q53S33 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 388962 | BOLA3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.82e-03 | 1.54e-01 | 0.0155 |
| 388962 | BOLA3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.68e-03 | 2.97e-01 | -0.0811 |
| 388962 | BOLA3 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.77e-14 | 3.96e-01 | -0.1954 |
| 388962 | BOLA3 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.03e-08 | 4.45e-01 | -0.1526 |
| 388962 | BOLA3 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.12e-10 | 3.97e-01 | -0.1464 |
| 388962 | BOLA3 | HTA11_866_2000001011 | Human | Colorectum | AD | 4.20e-04 | 2.32e-01 | -0.1001 |
| 388962 | BOLA3 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.74e-09 | 4.25e-01 | -0.059 |
| 388962 | BOLA3 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.06e-05 | 5.31e-01 | -0.1706 |
| 388962 | BOLA3 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.13e-03 | 3.02e-01 | -0.0179 |
| 388962 | BOLA3 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.44e-09 | 3.81e-01 | 0.096 |
| 388962 | BOLA3 | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.14e-03 | 3.86e-01 | 0.0528 |
| 388962 | BOLA3 | HTA11_7663_2000001011 | Human | Colorectum | SER | 3.08e-03 | 3.30e-01 | 0.0131 |
| 388962 | BOLA3 | HTA11_10623_2000001011 | Human | Colorectum | AD | 6.41e-03 | 2.64e-01 | -0.0177 |
| 388962 | BOLA3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 5.65e-05 | 2.35e-01 | 0.0674 |
| 388962 | BOLA3 | HTA11_7469_2000001011 | Human | Colorectum | AD | 1.13e-04 | 6.51e-01 | -0.0124 |
| 388962 | BOLA3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.26e-09 | 4.04e-01 | 0.294 |
| 388962 | BOLA3 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.49e-07 | 3.46e-01 | 0.281 |
| 388962 | BOLA3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.85e-14 | 4.65e-01 | 0.3859 |
| 388962 | BOLA3 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 9.43e-03 | 2.94e-01 | 0.2585 |
| 388962 | BOLA3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.70e-07 | 2.58e-01 | 0.3005 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BOLA3 | SNV | Missense_Mutation | novel | c.59C>T | p.Pro20Leu | p.P20L | Q53S33 | protein_coding | tolerated(0.28) | probably_damaging(0.996) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BOLA3 | SNV | Missense_Mutation | rs746179125 | c.71G>A | p.Arg24Gln | p.R24Q | Q53S33 | protein_coding | tolerated(0.07) | possibly_damaging(0.478) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| BOLA3 | SNV | Missense_Mutation | novel | c.196N>G | p.Lys66Glu | p.K66E | Q53S33 | protein_coding | tolerated(0.05) | benign(0.096) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BOLA3 | SNV | Missense_Mutation | c.182N>A | p.Ala61Glu | p.A61E | Q53S33 | protein_coding | deleterious(0.03) | probably_damaging(0.984) | TCGA-D1-A160-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BOLA3 | SNV | Missense_Mutation | novel | c.275T>C | p.Ile92Thr | p.I92T | Q53S33 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BOLA3 | SNV | Missense_Mutation | novel | c.69T>G | p.His23Gln | p.H23Q | Q53S33 | protein_coding | tolerated(0.41) | benign(0) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BOLA3 | SNV | Missense_Mutation | novel | c.145N>T | p.Ala49Ser | p.A49S | Q53S33 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BOLA3 | deletion | Frame_Shift_Del | novel | c.128delN | p.Lys43SerfsTer8 | p.K43Sfs*8 | Q53S33 | protein_coding | TCGA-D1-A17A-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| BOLA3 | SNV | Missense_Mutation | c.118N>G | p.Leu40Val | p.L40V | Q53S33 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-37-4135-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| BOLA3 | deletion | Frame_Shift_Del | novel | c.123delN | p.Glu42LysfsTer9 | p.E42Kfs*9 | Q53S33 | protein_coding | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |